Hans Schambye, Galecto CEO
October 8, 2020 07:15 AM EDT
Financing

Not two weeks af­ter clos­ing a Se­ries D round, Galec­to files for $100M IPO

Max Gelman

Senior Editor

Galec­to Biotech is piv­ot­ing to the pub­lic mar­ket less than two weeks af­ter com­plet­ing a $64 mil­lion Se­ries D round.

The Copen­hagen-based com­pa­ny filed its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times